pseudoephedrine (Sudafed, Afrin, Drixoral, SudoGest)

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8]

Introduction

Tradename: Sudafed. Restricted substance* (see alternatives to pseudoephedrine)

Indications

* avoid for treatment of allergic rhinitis[8]

Contraindications

use with caution in patients with:

pregnancy category = c

safety in lactation = -

Dosage

  • 60 mg PO every 4-6 hours.
  • 30 mg/dose if 6-13 yo.
  • 15 mg/dose if 2-5 yo.

Tabs: 30 & 60 mg.

Elixir: 30 mg/5 mL. Timed-release: Afrin, Drixoral. 120 mg PO BID. Tabs: 120 mg. Infant drops: (PediaCare Infant's decongestant) 7 drops/kg PO every 4-6 hours up to 4 doses/day if > 1 yo. 3 drops/kg if 3-12 months.

Pharmacokinetics

elimination via liver

Adverse effects

Drug interactions

Laboratory

Mechanism of action

* Because of the potential for chemical conversion to methamphetamine, pseudoephedrine & ephedrine are restricted substances. As of Sept 30, 2006, pseudoephedrine & ephedrine will be behind the counter. Only 3.6 g/day & 9 g/month will be dispensed. This works out to be 120 tablets of pseudoephedrine 30 mg per day, or 300 tabs/month.[5]

More general terms

Additional terms

Component of

References

  1. ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. ↑ Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  3. ↑ 3.0 3.1 Prescriber's Letter 10(10):60 2003
  4. ↑ 4.0 4.1 4.2 Salerno SM, Jackson JL, Berbano EP. Effect of oral pseudoephedrine on blood pressure and heart rate: a meta-analysis. Arch Intern Med. 2005 Aug 8-22;165(15):1686-94. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16087815
    Coates ML, Rembold CM, Farr BM. Does pseudoephedrine increase blood pressure in patients with controlled hypertension? J Fam Pract. 1995 Jan;40(1):22-6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/7807033
  5. ↑ 5.0 5.1 Prescriber's Letter 13(4): 2006 New Rules for the Sale of Pseudoephedrine and other Methamphetamine Precursors Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220413&pb=PRL (subscription needed) http://www.prescribersletter.com
  6. ↑ 6.0 6.1 6.2 Deprecated Reference
  7. ↑ 7.0 7.1 Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
    Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016
  8. ↑ 8.0 8.1 Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/

Database

Retrieved from "https://aaushi.info/w/index.php?title=A16418&oldid=1230001"